Compass Pathways Establishes Strategic Collaboration with HealthPort to Inform the Potential Delivery of COMP360 Synthesized Psilocybin Treatment in Underserved Communities

Contributed by: Business Wire

Tags

Mental Health
Research
Clinical Trials
Biotechnology
Managed Care
Health
Pharmaceutical
General Health
Science
HealthPort

More Like This

Compass Pathways to Participate in Cowen Psychedelics and Novel Mechanisms in Neuropsychiatry Summit

Compass Pathways Announces Completion of Recruitment for the Phase 3 COMP005 Trial of COMP360 Psilocybin for Treatment-Resistant Depression

Compass Pathways Announces Dosing Complete for All Participants in Part A of Phase 3 COMP005 Trial of COMP360 Psilocybin for Treatment-Resistant Depression

Compass Pathways Announces Publication of Results from COMP004 Study on COMP360 Psilocybin for Treatment-Resistant Depression

Business Wire logo

Compass Pathways Announces Third Quarter 2024 Financial Results and Business Updates

Compass Pathways Announces Fourth Quarter and Full-Year 2024 Financial Results and Business Highlights

Compass Pathways Appoints Steve Levine, M.D., as Chief Patient Officer

Compass Pathways Announces Pricing of Underwritten Offering